James Bradner,
M.D., Joins as Executive Vice President, Research and Development,
and Chief Scientific Officer
David M. Reese, M.D., Named Executive
Vice President and Chief Technology Officer
THOUSAND
OAKS, Calif., Dec. 14,
2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today
announced two changes to its senior leadership team in the areas of
research and development (R&D) and technology, underscoring the
advancement of the company's robust pipeline and its commitment to
ongoing scientific and technological innovation. James Bradner, M.D., has joined Amgen as
executive vice president of Research and Development, and chief
scientific officer. Bradner is succeeding David M. Reese, M.D., who has been appointed
executive vice president and chief technology officer. Both Bradner
and Reese will report to Robert A.
Bradway, chairman and chief executive officer at Amgen.
"For more than 40 years, Amgen's focus on innovation has enabled
us to deliver life-changing medicines to patients suffering from
serious diseases around the world," said Robert A. Bradway,
chairman and chief executive officer at Amgen. "The steps we are
announcing today reflect our conviction that the rapid convergence
of 'biotech' and 'tech' will unlock the next frontier of innovation
in biotechnology."
Bradner is a seasoned R&D leader who will be responsible for
advancing Amgen's pipeline, which includes potential first-in-class
medicines in all stages of development and across the company's
four therapeutic areas of focus: oncology, inflammation, general
medicine and rare disease, in addition to biosimilars. He will also
be responsible for Amgen's worldwide research efforts.
Reese joined Amgen in 2005 and has led the R&D organization
since 2018. During his tenure, Amgen has received approvals around
the world for numerous innovative medicines and biosimilars.
Building on Amgen's commitment to leveraging human data in drug
discovery and development, Reese has led the development of a
robust pipeline. Recently he has also been the key architect of
Amgen's artificial intelligence (AI) and advanced technology
initiatives with a focus on R&D. He will now be responsible for
accelerating the use of technology and AI across all facets of the
organization.
James Bradner, M.D., Joins as
Executive Vice President, Research and Development, and Chief
Scientific Officer
"Amgen has distinguished, long-standing strengths in
biotechnology, with world-class scientists pioneering solutions for
patients suffering from serious illnesses," said James Bradner, M.D., incoming executive vice
president of Research and Development, and chief scientific officer
at Amgen. "I look forward to further advancing our robust pipeline
and research capabilities."
An experienced scientific leader, Bradner served as President of
the Novartis Institutes for BioMedical Research, where he was a
member of the Executive Committee of Novartis. His research and
leadership have contributed to numerous development programs,
multiple investigational new drug applications and positive
proof-of-concept studies in clinical investigation. For the past
year, he has been a clinician at the Dana-Farber Cancer Institute
and was previously an associate professor at Harvard Medical School. As an entrepreneur, he has
co-founded and built several biotechnology startups.
David Reese, M.D., Appointed
Executive Vice President and Chief Technology Officer
"We are at a hinge moment in the biopharmaceutical industry,
where we are seeing profound changes in drug discovery and
development powered by the union of technology and biotechnology.
At Amgen we have been preparing for this moment for over a decade,"
said David M. Reese, executive vice
president and chief technology officer at Amgen. "We will continue
to advance these investments in R&D, while also pursuing
opportunities across the company where technology can enable us to
work more efficiently and effectively on behalf of the patients we
serve."
Reese has been instrumental in driving a culture of innovation
over his 18-year tenure at Amgen. Under his leadership, the company
has built a robust pipeline and a powerful discovery research and
development capability. This includes the induced proximity
platform, next-generation capabilities in both small molecule and
protein molecular engineering, a world-leading human data
capability and the use of innovative clinical trial designs.
About Amgen
Amgen is committed to unlocking the potential of biology for
patients suffering from serious illnesses by discovering,
developing, manufacturing and delivering innovative human
therapeutics. This approach begins by using tools like advanced
human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and
leverages its expertise to strive for solutions that improve health
outcomes and dramatically improve people's lives. A biotechnology
pioneer since 1980, Amgen has grown to be one
of the world's leading independent biotechnology
companies, has reached millions of patients around the world and is
developing a pipeline of medicines with breakaway
potential.
Amgen is one of the 30 companies that comprise the Dow
Jones Industrial Average and is also part of the Nasdaq-100 index.
In 2023, Amgen was named one of "America's Greatest Workplaces" by
Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best
Companies" by TIME.
For more information, visit Amgen.com and follow us on X
(formerly known as Twitter), LinkedIn, Instagram, TikTok,
YouTube and Threads.
Amgen Forward-Looking Statements
This news release
contains forward-looking statements that are based on the current
expectations and beliefs of Amgen. All statements, other than
statements of historical fact, are statements that could be deemed
forward-looking statements, including any statements on the
outcome, benefits and synergies of collaborations, or potential
collaborations, with any other company (including BeiGene, Ltd. or
Kyowa Kirin Co., Ltd.), the performance of Otezla®
(apremilast) (including anticipated Otezla sales growth and the
timing of non-GAAP EPS accretion), our acquisitions of Teneobio,
Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including
the prospective performance and outlook of Horizon's business,
performance and opportunities and any potential strategic benefits,
synergies or opportunities expected as a result of such
acquisition), as well as estimates of revenues, operating margins,
capital expenditures, cash, other financial metrics, expected
legal, arbitration, political, regulatory or clinical results or
practices, customer and prescriber patterns or practices,
reimbursement activities and outcomes, effects of pandemics or
other widespread health problems on our business, outcomes,
progress, and other such estimates and
results. Forward-looking statements involve significant risks
and uncertainties, including those discussed below and more fully
described in the Securities and Exchange Commission reports filed
by Amgen, including our most recent annual report on Form 10-K and
any subsequent periodic reports on Form 10-Q and current reports on
Form 8-K. Unless otherwise noted, Amgen is providing this
information as of the date of this news release and does not
undertake any obligation to update any forward-looking statements
contained in this document as a result of new information, future
events or otherwise.
No forward-looking statement can be guaranteed and actual
results may differ materially from those we project. Our results
may be affected by our ability to successfully market both new and
existing products domestically and internationally, clinical and
regulatory developments involving current and future products,
sales growth of recently launched products, competition from other
products including biosimilars, difficulties or delays in
manufacturing our products and global economic conditions. In
addition, sales of our products are affected by pricing pressure,
political and public scrutiny and reimbursement policies imposed by
third-party payers, including governments, private insurance plans
and managed care providers and may be affected by regulatory,
clinical and guideline developments and domestic and international
trends toward managed care and healthcare cost containment.
Furthermore, our research, testing, pricing, marketing and other
operations are subject to extensive regulation by domestic and
foreign government regulatory authorities. We or others could
identify safety, side effects or manufacturing problems with our
products, including our devices, after they are on the market. Our
business may be impacted by government investigations, litigation
and product liability claims. In addition, our business may be
impacted by the adoption of new tax legislation or exposure to
additional tax liabilities. If we fail to meet the compliance
obligations in the corporate integrity agreement between us and the
U.S. government, we could become subject to significant sanctions.
Further, while we routinely obtain patents for our products and
technology, the protection offered by our patents and patent
applications may be challenged, invalidated or circumvented by our
competitors, or we may fail to prevail in present and future
intellectual property litigation. We perform a substantial amount
of our commercial manufacturing activities at a few key facilities,
including in Puerto Rico, and also
depend on third parties for a portion of our manufacturing
activities, and limits on supply may constrain sales of certain of
our current products and product candidate development. An outbreak
of disease or similar public health threat, such as COVID-19, and
the public and governmental effort to mitigate against the spread
of such disease, could have a significant adverse effect on the
supply of materials for our manufacturing activities, the
distribution of our products, the commercialization of our product
candidates, and our clinical trial operations, and any such events
may have a material adverse effect on our product development,
product sales, business and results of operations. We rely on
collaborations with third parties for the development of some of
our product candidates and for the commercialization and sales of
some of our commercial products. In addition, we compete with other
companies with respect to many of our marketed products as well as
for the discovery and development of new products. Discovery or
identification of new product candidates or development of new
indications for existing products cannot be guaranteed and movement
from concept to product is uncertain; consequently, there can be no
guarantee that any particular product candidate or development of a
new indication for an existing product will be successful and
become a commercial product. Further, some raw materials, medical
devices and component parts for our products are supplied by sole
third-party suppliers. Certain of our distributors, customers and
payers have substantial purchasing leverage in their dealings with
us. The discovery of significant problems with a product similar to
one of our products that implicate an entire class of products
could have a material adverse effect on sales of the affected
products and on our business and results of operations. Our efforts
to collaborate with or acquire other companies, products or
technology, and to integrate the operations of companies or to
support the products or technology we have acquired, may not be
successful. There can be no guarantee that we will be able to
realize any of the strategic benefits, synergies or opportunities
arising from the Horizon acquisition, and such benefits, synergies
or opportunities may take longer to realize than expected. We
may not be able to successfully integrate Horizon, and such
acquisition or integration may take longer, be more difficult or
cost more than expected. A breakdown, cyberattack or information
security breach of our information technology systems could
compromise the confidentiality, integrity and availability of our
systems and our data. Our stock price is volatile and may be
affected by a number of events. Our business and operations may be
negatively affected by the failure, or perceived failure, of
achieving our environmental, social and governance objectives. The
effects of global climate change and related natural disasters
could negatively affect our business and operations. Global
economic conditions may magnify certain risks that affect our
business. Our business performance could affect or limit the
ability of our Board of Directors to declare a dividend or our
ability to pay a dividend or repurchase our common stock. We may
not be able to access the capital and credit markets on terms that
are favorable to us, or at all.
CONTACT: Amgen, Thousand
Oaks
Jessica Akopyan, 805-440-5721
(media)
Justin Claeys, 805-313-9775
(investors)
View original content to download
multimedia:https://www.prnewswire.com/news-releases/amgen-announces-executive-appointments-to-accelerate-innovation-302015390.html
SOURCE Amgen